Product information and disease descriptionProduct descriptionProduct informationPharmacology
Mechanism of action
8 evidence topics · 7 sources
Dual agonist of the GLP-1 and GIP receptors
Receptor binding affinity and half-life extension
“VK2735 binds with high affinity to both the GLP‐1 receptor (IC50: 188 nM) and GIP receptor (IC50: 325 nM) (unpublished data, Viking Therapeutics, Inc.).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The VK2735 peptide incorporates the activities of both incretins and contains a side chain that imparts an extended half‐life when administered as a subcutaneous injection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Physiological rationale for combined GLP-1 and GIP receptor activation
Selection of VK2735 from an internally developed dual agonist series
Subcutaneous formulation: peptide administered once weekly
Oral formulation: same peptide administered once daily as a tablet
Peptide sequence, structure, and oral absorption technology
No evidence found.